# Using ctDNA to Determine Therapies for Lung Cancer

> **NCT04966663** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 66 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Complete Surgical Resection
- Circulating Tumor DNA

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **PROCEDURE:** ctDNA blood test

## Key facts

- **NCT ID:** NCT04966663
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04966663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04966663, "Using ctDNA to Determine Therapies for Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04966663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*